Yes we know it’s a bit retrospective, but given the recent serial Q3 financial press releases, we found it interesting to reflect on Orthopaedic website Bonezone’s table summarising the winners and losers from Q2 data. The table can be found here and details the quarter against the equivalent period a year ago. Particularly useful is the way the table does this by segment where available, so knees, hips etc.
The market growth which forms the benchmark for the 29 companies listed is 5% and of course it must be remembered that this is not a comprehensive account of all financials of all orthopaedic companies. However from the list we can see that Bacterin, developer of bone graft materials and antimicrobial coatings for medical application, showed the biggest growth of 135% albeit on a relatively small revenue figure compared with the bigger enterprises.
Mako Surgical showed impressive 81% year on year growth with its robotic arm and proprietary “Makoplasty” joint resurfacing technology. Mako was recently ranked No. 1 on Deloitte’s Technology Fast 500™, ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America.
Third overall in the list was China Kanghui holdings, a Changzhou-based developer, manufacturer and marketer of orthopedic implants. The company continues to see very strong growth in its home market and in its most recent financial report was forecasting 31% full year growth over 2010, despite a decrease in international sales of its proprietary products which has been more than offset by significant growth in OEM sales.
Of the fallers, spine company Trans-1 had the toughest Q2, which was to continue through Q3 with another sales decrease of 26%, due according to the financial statements to challenging conditions in the spine market as well as the limited physician reimbursement for their procedure.
Taking a snapshot of the data, the big fish don’t look to be having an easy time out there, with Medtronic showing a 3% year on year decrease alongside Biomet(-3%) and Conmed(-3%) while Wright were static, Zimmer showed modest growth(2%) and only Stryker showed meaningful above market growth of 12%.
We’ll try and update for Q3 shortly.
Source: Bonezone, medlatest